T2DM Management.

Slides:



Advertisements
Similar presentations
New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia.
Advertisements

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.
ORIGIN Outcome Reduction with an Initial Glargine Intervention (ORIGIN) Trial Overview Large international randomized controlled trial in patients with.
Biphasic insulin aspart 30 + metformin vs once-daily insulin glargine + glimepiride Kann P, Regulski M, Medding J, Ligthelm R A study in people with type.
Introduction Subcutaneous insulin absorption is not reproducible and insulin entry directly into the circulation is not linked to glucose sensing Basal.
What's New in Basal Insulin for Diabetes
Short-, Intermediate-, Long-Acting Insulins
Updates and Perspectives in Diabetic Dyslipidemia
Engaging the INSULIN-TREATED T2DM Patient: the Importance of Real-World Data.
Applying Data to Practice
Current Dyslipidemia Management Guidelines Residual Risk.
Faster-Acting Insulins
Program Goals. Inhaled Insulin: Overcoming Past Obstacles With Advances in Understanding.
Using the AGP to Standardize Glucose Reporting
The Next Generation of Basal Insulins
Global Projections for Diabetes:
Modern Strategies for Basal Insulin Use in T2D
PAD Patients vs Post-ACS Patients:
Insulin Innovation.
Insulin/GLP-1 Agonist Combinations
Insulin Intensification Strategies in Later-Stage Type 2 Diabetes Mellitus.
SGLT2 Inhibitors in Phase 3 Trials
How Early Should Basal Insulin Be Used in T2D Management?
Novel Concentrated Insulins: What Benefits and for Which Patients?
Examining CV Effects of Basal Insulin Therapy
What Do Primary Care Physicians Need to Know About Insulin/GLP-1 RA Fixed-Ratio Combinations?
Innovative Insulin Combinations: A New strategy for the Person With T2DM.
Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?
Metabolically Healthy Patients With Obesity
Emerging Basal Insulins for Diabetes
Faster-Acting Insulins
ADA/EASD Position Statement: Approach to Hyperglycemia Management
Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.
A New Chapter for CV Risk Management in Diabetes - Challenges & Opportunities.
Novel Insulin Combinations: What Does the Primary Care Physician Need to Know?
Integrated Diabetes Care: How Can We Make the Best Use of New Technology?
Drug-Coated Balloons:
Insulin/GLP-1 Agonist Combinations
Insulin Innovation.
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus
LEADER One Year On.
Predictive Low Glucose Suspend (PLGS)
GLP-1 Receptor Agonists: A Tool for the Primary Care Physician to Reduce CV Risk in Diabetes?
Novel Approaches to T1D Management
Aspirin and Cardioprevention in 2018
Better Diabetes Control With Novel Basal Insulins
Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?
Optimizing Insulin Therapy in Primary Care: Basal Plus Incretin Combinations.
Younger Patients With Type 1 Diabetes: Can We Optimize Their Insulin Therapy?
Dual SGLT1/SGLT2 Inhibition in T1D
Insulin Innovation.
Statins, Obesity, and Hyperlipidemia
PEARLS OF WISDOM WITH COMBINATION THERAPY IN PAH
COMBINATIONS AND COFORMULATIONS: THE FUTURE OF INSULIN THERAPY?
Add-On Therapy to Insulin in T1DM Management
Are All Novel Insulins Proven to Be Equally Safe?
2015 EASD In Review: CV Risk management in t2dm
Real-World Evidence.
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
New Approaches for Type 2 Diabetes -- GLP-1 RAs Now and in the Future
Identifying TRK Fusions in Head and Neck Cancer
Fixed-Ratio Combination Therapy in T2DM
BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS
Emerging Basal Insulins for Diabetes
The Elevated Role of GLP-1 RAs in Diabetes Management: Which Patients Should We Aim For?
Fresh perspectives ON BASAL Insulins in diabetes care
Time course of daily basal and mealtime insulin dose (A), glycated hemoglobin (B), laboratory-measured clinic FPG (C), prebreakfast SMPG (D), SMPG profiles.
The Power of As-Treated Analyses
The Challenge of Insulin Titration
Presentation transcript:

T2DM Management

Program Overview

The Development of Basal Insulins

Continuum of Clinical Research: RCTs and RWE

BEGIN and EDITION Trials for Deg-100 and Gla-300

RWE for Gla-300: DELIVER Studies

DEVOTE Trial: Deg-100 vs Gla-100

Comparing PK/PD Data

Cannot Directly Compare BEGIN and EDITION Programs

BRIGHT: Head-to-Head Comparison of Gla-300 and Deg-100

BRIGHT: Study Endpoints and Glycemic Targets

BRIGHT: Baseline Characteristics

BRIGHT: Primary Endpoint: Glycemic Control

BRIGHT: FPG and SMBG Reduction

BRIGHT: 8-Point SMBG and Variability Profiles

BRIGHT: Anytime (24 h) Hypoglycemia

BRIGHT: Nocturnal (00:00–06:00 h) Hypoglycemia

BRIGHT: TEAEs

BRIGHT: Insulin Dosage and Body Weight Over 24 Weeks

BRIGHT: Results Summary

Conclusions

Abbreviations

Abbreviations (cont)